US tariff proposal wake-up call for Indian pharma to diversify, innovate: Experts

US pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market reliance. There are warnings that ensuring patient access to affordable medications should remain paramount.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yst4R6k
via IFTTT

Read More

Sculpt, lift, glow: Face fitness is having a moment in India

Face fitness is emerging as a new category in India’s beauty and wellness market, blending facial massage, muscle stimulation and skincare into studio-led treatments. Premium brands and homegrown players are expanding as consumers seek non-invasive alternatives to aesthetic procedures, driven by growing interest in wellness, grooming and preventive beauty.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lzFpKvR
via IFTTT

Read More

Aster DM Quality Care to invest Rs 1,315 crore in Karnataka

Aster DM Quality Care will invest Rs 1,315 crore in Karnataka's healthcare infrastructure. This significant investment aims to strengthen the state's medical facilities and services. The company plans to develop new hospitals and expand existing ones in Bengaluru. These developments will enhance access to advanced tertiary and quaternary care. The commitment underscores Aster's long-term confidence in Karnataka's healthcare ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gX19DFN
via IFTTT

Read More

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company aims for significant revenue growth by 2030 through new drug launches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/deDbnmy
via IFTTT

Read More

FSSAI suspends Rehaan Healthcare licence over serious food safety violations

FSSAI has suspended Rehaan Healthcare’s licence after inspections revealed serious violations at its health supplements and nutraceutical manufacturing facility. The regulator found extremely unhygienic conditions, poor infrastructure, pest infestation, inadequate storage, and major food safety lapses, resulting in a very low compliance score of 12%. The company has been ordered to halt production until all deficiencies are rectified and verified by the competent authority, failing which legal action may follow.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u5PjhQJ
via IFTTT

Read More

Jackson Labs seeks restoration of its licence

The cancellation issued by the Punjab government followed reports that five women in Kota, Rajasthan, died after allegedly being administered an Oxytocin injection that upon testing found contained no active ingredient.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T9z30Rj
via IFTTT

Read More

India contributes one-third of global oral cancer burden; early detection key to survival, says oral cancer expert

India contends with a pressing oral cancer crisis, with thousands of new diagnoses and deaths emerging annually. The predominant factor behind this disease is the consumption of tobacco in diverse forms. Early detection via screening plays a critical role in managing and treating oral cancers successfully. It’s vital to monitor potentially malignant disorders closely and seek rapid medical assistance for ongoing oral health issues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8OHqfZa
via IFTTT

Read More